INT16177

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1991
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 6
Disease Relevance 0.98
Pain Relevance 0.41

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endoplasmic reticulum (UGT1A3) enzyme binding (UGT1A3)
Anatomy Link Frequency
hepatocyte 2
liver 1
UGT1A3 (Homo sapiens)
Pain Link Frequency Relevance Heat
Bile 36 91.20 High High
cINOD 4 84.80 Quite High
Morphine 6 47.84 Quite Low
agonist 52 5.00 Very Low Very Low Very Low
Kinase C 16 5.00 Very Low Very Low Very Low
Inflammation 8 5.00 Very Low Very Low Very Low
Paracetamol 8 5.00 Very Low Very Low Very Low
dexamethasone 4 5.00 Very Low Very Low Very Low
Opioid 4 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Van Bogaert's Disease 28 98.96 Very High Very High Very High
Targeted Disruption 8 92.72 High High
Hepatotoxicity 4 87.52 High High
Gallstones 8 84.52 Quite High
INFLAMMATION 10 75.00 Quite High
Syndrome 8 65.88 Quite High
Colon Cancer 1 65.08 Quite High
Hyperbilirubinemia 4 63.84 Quite High
Sprains And Strains 8 25.76 Quite Low
Toxicity 8 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The UGT1A3 mRNA content was enhanced by beta-naphthoflavone; by contrast, that of UGT2B7 was insensitive to the inducer.
Positive_regulation (enhanced) of UGT1A3
1) Confidence 0.57 Published 2000 Journal Life Sci. Section Abstract Doc Link 10901286 Disease Relevance 0.20 Pain Relevance 0.28
The activity of UDPGT was tissue- and substrate-dependent.
Positive_regulation (dependent) of UDPGT
2) Confidence 0.46 Published 1991 Journal Eur. J. Clin. Pharmacol. Section Abstract Doc Link 1804651 Disease Relevance 0 Pain Relevance 0
The formation of chenodeoxycholic acid (CDCA) glucuronide by UGT1A3 has been shown to decrease farnesoid X receptor (FXR) activation by CDCA, the prototypical FXR ligand [99], suggesting that UGT1A3 induction in human liver would be expected to have down-stream consequences for an array of gene expression networks that are transcriptionally regulated by FXR.

4.2.

Positive_regulation (induction) of UGT1A3 in liver associated with van bogaert's disease
3) Confidence 0.31 Published 2009 Journal PPAR Research Section Body Doc Link PMC2724710 Disease Relevance 0.59 Pain Relevance 0.13
activators produced modest increases in hepatic UGT1A1 and UGT1A3 mRNA levels [122].
Positive_regulation (increases) of UGT1A3
4) Confidence 0.23 Published 2009 Journal PPAR Research Section Body Doc Link PMC2724710 Disease Relevance 0 Pain Relevance 0
In a recent study by Senekeo-Effenberger et al. [125], Wy-14,643 treatment of primary cultured human hepatocytes increased the levels of UGT1A1, UGT1A3, UGT1A4, and UGT1A6, but not UGT1A9, mRNAs.
Positive_regulation (increased) of UGT1A3 in hepatocytes
5) Confidence 0.21 Published 2009 Journal PPAR Research Section Body Doc Link PMC2724710 Disease Relevance 0.09 Pain Relevance 0
At the mRNA level in liver, very strong (>100-fold) induction of UGT1A1 and UGT1A3, significant (~3- to 4-fold) induction of UGT1A4 and UGT1A6, and no induction of UGT1A9 were seen, in general agreement with the above-described effects in the human hepatocyte cultures [125].
Positive_regulation (induction) of UGT1A3 in hepatocyte
6) Confidence 0.21 Published 2009 Journal PPAR Research Section Body Doc Link PMC2724710 Disease Relevance 0.09 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox